Would you consider adjuvant osimertinib for patients with non-classical but sensitizing EGFR mutation positive NSCLC s/p surgical resection?  

While uncommon, EGFR mutations were not included in the ADAURA trial (and thus may not be covered by 3rd party insurance), I will consider using osimertinib in the adjuvant setting for high risk patients with certain atypical/uncommon EGFR mutations, i.e. mutations wherein structure-based modeling a...